Core Viewpoint - Elicio Therapeutics, Inc. has initiated an underwritten public offering of its common stock and accompanying warrants, with the offering subject to market conditions and no assurance of completion or specific terms [1][2]. Company Overview - Elicio Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer treatment, utilizing its AMP technology to enhance the immune system's response against tumors [10]. - The company's R&D pipeline includes therapeutic cancer vaccines such as ELI-002, targeting mKRAS-driven cancers, and ELI-007 and ELI-008, targeting BRAF-driven cancers and p53 hotspot mutations, respectively [10]. Offering Details - A shelf registration statement for the securities has been filed with the SEC, effective June 11, 2024, with a preliminary prospectus supplement to be made available [2]. - JonesTrading Institutional Services LLC is acting as the sole book-running manager for the offering [4]. Use of Proceeds - The net proceeds from the offering, along with existing cash and marketable securities, will be used to advance the development pipeline, working capital, and general corporate purposes [8].
Elicio Therapeutics Announces Proposed Public Offering